ANI Pharmaceuticals announced the results of the NEW DAY clinical trial for ILUVIEN® (fluocinolone acetonide) in diabetic macular edema (DME) patients during the ASRS Annual Scientific Meeting. The ...

A post-hoc analysis was conducted on a subset of randomized patients without major protocol deviations—such as being enrolled or randomized despite not meeting eligibility criteria, receiving ...

The trial involved 306 eyes from those who were either treatment-naïve or almost naïve at nearly 42 US sites. Credit: Prostock-studio/Shutterstock.com. · Clinical ...

More patients receiving either the High Dose or Low Dose Iluvien showed improvement in best corrected visual acuity of 15 or more letters at 2 years compared to those receiving sham treatment. This ...

ATLANTA, July 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ...

Please provide your email address to receive an email when new articles are posted on . Two-year interim outcomes of the PALADIN study showed that sustained, continuous release of fluocinolone ...

The primary endpoint of the trial was the mean total number of supplemental aflibercept injections needed for the treatment of DME in the ILUVIEN arm compared to the aflibercept arm over the 18-month ...

PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study ...